On Thursday, the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) announced topline results from a preliminary analysis of the PALM 007 trial of tecovirimat for the treatment of monkeypox virus (mpox). SIGA Technologies (NASDAQ:SIGA) sells tecovirimat under Tpoxx, an antiviral medication against orthopoxviruses such as smallpox and mpox. NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of th…
